Atopic Dermatitis
Conditions
Interventions
Clinical and molecular phenotype analysis:Sample collection, routine therapy
Dupilumab group:Dupilumab treatment
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
2 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients meeting the diagnostic criteria for AD (Japanese guidelines for atopic dermatitis 2016), 1) pruritus, 2) typical morphology and distribution of the eczema, and 3) chronic or chronically relapsing course. 2. Age from 2 to 80 years, male or female, Chinese Han population. 3. Patients are able to understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Combined with other skin diseases, such as psoriasis, vitiligo, lupus erythematosus. 2. Patients with autoimmune diseases, such as rheumatoid arthritis. 3. Pregnant or lactating women. 4. Parasitic infection. 5. A history of severe systemic disease or malignant tumor. 6. Participated in other clinical trials in the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Scoring Atopic Dermatitis (SCORAD) score;Investigator's global assessment (IGA) score;Dermatology life quality index (DLQI) score;Inflammatory molecules ;Eczema Area and Severity Index (EASI);T-cell subsets;Histopathologic;Cytokines and chemokines;Patient-Oriented Eczema Measure, POEM; | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes of the level of itching and its effect on sleep;IgE;Fecal flora metagenomics;Skin flora metagenomics; | — |
Countries
CHINA
Contacts
Public ContactWei Li
Huashan Hospital, Fudan University
Outcome results
None listed